Microparticles: An Alternative Explanation to the Behavior of Vascular Antiphospholipid Syndrome

 

 Buy Article Permissions and Reprints

Abstract

Antiphospholipid syndrome is an autoimmune disease characterized by the persistent presence of antiphospholipid antibodies, along with occurrence of vascular thrombosis and pregnancy morbidity. The variety of antiphospholipid antibodies and their related mechanisms, as well as the behavior of disease in wide groups of patients, have led some authors to propose a differentiation of this syndrome into two independent entities: vascular and obstetric antiphospholipid syndrome. Thus, previous studies have discussed whether specific autoantibodies may be responsible for this differentiation or, in contrast, how the same antibodies are able to generate two different clinical presentations. This discussion is yet to be settled. The capability of serum IgG from patients with vascular thrombosis to trigger the biogenesis of endothelial cell-derived microparticles in vitro is one of the previously discussed differences between the clinical entities of antiphospholipid syndrome. These vesicles constitute a prothrombotic mechanism as they can directly lead to clot activation in murine models and recalcified human plasma. Nevertheless, other indirect mechanisms by which microparticles can spread a procoagulant phenotype could be critical to understanding their role in antiphospholipid syndrome. For this reason, questions regarding the cargo of microparticles, and the signaling pathways involved in their biogenesis, are of interest in attempting to explain the behavior of this autoimmune disease.

Authors' Contributions

Á.P.C.J. and D.Á. proposed the main topic of this review; D.Á. prepared the draft copy of the manuscript; and C.R. and Á.P.C.J. critically assessed and evaluated the writing process.

Publication History

Article published online:
30 April 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Chargaff E, West R. The biological significance of the thromboplastic protein of blood. J Biol Chem 1946; 166 (01) 189-197
  CrossrefPubMedGoogle Scholar
• 2 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13 (03) 269-288
  CrossrefPubMedGoogle Scholar
• 3 Dvorak HF, Quay SC, Orenstein NS. et al. Tumor shedding and coagulation. Science 1981; 212 (4497): 923-924
  CrossrefPubMedGoogle Scholar
• 4 Pardo F, Villalobos-Labra R, Sobrevia B, Toledo F, Sobrevia L. Extracellular vesicles in obesity and diabetes mellitus. Mol Aspects Med 2018; 60: 81-91
  CrossrefPubMedGoogle Scholar
• 5 Burbano C, Rojas M, Muñoz-Vahos C. et al. Extracellular vesicles are associated with the systemic inflammation of patients with seropositive rheumatoid arthritis. Sci Rep 2018; 8 (01) 17917
  CrossrefPubMedGoogle Scholar
• 6 Atehortúa L, Rojas M, Vásquez G. et al. Endothelial activation and injury by microparticles in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2019; 21 (01) 34
  CrossrefPubMedGoogle Scholar
• 7 Cicarini WB, Ferreira KS, Loures CMG. et al. Systemic lupus erythematosus: disease activity may influence the release of endothelial microparticles?. Blood Coagul Fibrinolysis 2018; 29 (02) 189-195
  CrossrefPubMedGoogle Scholar
• 8 Chaturvedi S, Alluri R, McCrae KR. Extracellular vesicles in the antiphospholipid syndrome. Semin Thromb Hemost 2018; 44 (05) 493-504
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Pericleous C, Clarke LA, Brogan PA. et al. Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. Thromb Haemost 2013; 109 (01) 72-78
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R. et al; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 1000 consecutive cases. Autoimmun Rev 2019; 18 (04) 406-414
  CrossrefPubMedGoogle Scholar
• 11 Meroni PL, Borghi MO, Grossi C, Chighizola CB, Durigutto P, Tedesco F. Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nat Rev Rheumatol 2018; 14 (07) 433-440
  CrossrefPubMedGoogle Scholar
• 12 Poulton K, Ripoll VM, Pericleous C. et al. Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. Am J Reprod Immunol 2015; 73 (05) 390-401
  Google Scholar
• 13 Lambrianides A, Carroll CJ, Pierangeli SS. et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010; 184 (12) 6622-6628
  CrossrefPubMedGoogle Scholar
• 14 Fischetti F, Durigutto P, Pellis V. et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106 (07) 2340-2346
  CrossrefPubMedGoogle Scholar
• 15 Ye R, Ye C, Huang Y, Liu L, Wang S. Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis. Thromb Res 2012; 130 (02) 253-258
  CrossrefPubMedGoogle Scholar
• 16 Khorana AA, Francis CW, Menzies KE. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6 (11) 1983-1985
  CrossrefPubMedGoogle Scholar
• 17 Bucciarelli P, Martinelli I, Artoni A. et al. Circulating microparticles and risk of venous thromboembolism. Thromb Res 2012; 129 (05) 591-597
  CrossrefPubMedGoogle Scholar
• 18 Thomas GM, Brill A, Mezouar S. et al. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost 2015; 13 (07) 1310-1319
  CrossrefPubMedGoogle Scholar
• 19 Breen KA, Sanchez K, Kirkman N. et al. Endothelial and platelet microparticles in patients with antiphospholipid antibodies. Thromb Res 2015; 135 (02) 368-374
  CrossrefPubMedGoogle Scholar
• 20 Willemze R, Bradford RL, Mooberry MJ, Roubey RAS, Key NS. Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications. Thromb Res 2014; 133 (02) 187-189
  CrossrefPubMedGoogle Scholar
• 21 Dignat-George F, Camoin-Jau L, Sabatier F. et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91 (04) 667-673
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Vikerfors A, Mobarrez F, Bremme K. et al. Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus 2012; 21 (07) 802-805
  CrossrefPubMedGoogle Scholar
• 23 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
  CrossrefPubMedGoogle Scholar
• 24 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78 (10) 1296-1304
  CrossrefPubMedGoogle Scholar
• 25 von Landenberg C, Lackner KJ, von Landenberg P, Lang B, Schmitz G. Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease. J Autoimmun 1999; 13 (02) 215-223
  CrossrefPubMedGoogle Scholar
• 26 Durigutto P, Grossi C, Borghi MO. et al. New insight into antiphospholipid syndrome: antibodies to β2 glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica 2019; 104 (04) 819-826
  CrossrefPubMedGoogle Scholar
• 27 Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey M-A. Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol 2018; 9: 2971
  CrossrefPubMedGoogle Scholar
• 28 Alessandri C, Agmon-Levin N, Conti F. et al. Anti-mutated citrullinated vimentin antibodies in antiphospholipid syndrome: diagnostic value and relationship with clinical features. Immunol Res 2017; 65 (02) 524-531
  CrossrefPubMedGoogle Scholar
• 29 Rodríguez-García V, Ioannou Y, Fernández-Nebro A, Isenberg DA, Giles IP. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology (Oxford) 2015; 54 (11) 2042-2050
  CrossrefPubMedGoogle Scholar
• 30 Žigon P, Podovšovnik A, Ambrožič A. et al. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Clin Rheumatol 2019; 38 (02) 371-378
  CrossrefPubMedGoogle Scholar
• 31 Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL. et al. Closing the serological gap in the antiphospholipid syndrome: the value of “non-criteria” antiphospholipid antibodies. J Rheumatol 2017; 44 (11) 1597-1602
  CrossrefPubMedGoogle Scholar
• 32 de Groot PG, Urbanus RT. Antiphospholipid syndrome--not a noninflammatory disease. Semin Thromb Hemost 2015; 41 (06) 607-614
  Article in Thieme ConnectPubMedGoogle Scholar
• 33 Hollerbach A, Müller-Calleja N, Ritter S. et al. Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors. Thromb Haemost 2019; 119 (07) 1147-1153
  Article in Thieme ConnectPubMedGoogle Scholar
• 34 Müller-Calleja N, Hollerbach A, Häuser F, Canisius A, Orning C, Lackner KJ. Antiphospholipid antibody-induced cellular responses depend on epitope specificity: implications for treatment of antiphospholipid syndrome. J Thromb Haemost 2017; 15 (12) 2367-2376
  CrossrefPubMedGoogle Scholar
• 35 Drozidinsky G, Hadar E, Shmueli A, Gabbay-Benziv R, Shiber S. Obstetric antiphospholipid syndrome and long term arterial thrombosis risk. J Thromb Thrombolysis 2017; 44 (03) 371-375
  CrossrefPubMedGoogle Scholar
• 36 Out HJ, Kooijman CD, Bruinse HW, Derksen RHWM. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41 (03) 179-186
  CrossrefPubMedGoogle Scholar
• 37 Girardi G, Berman J, Redecha P. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112 (11) 1644-1654
  CrossrefPubMedGoogle Scholar
• 38 Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10 (11) 1222-1226
  CrossrefPubMedGoogle Scholar
• 39 Agostinis C, Durigutto P, Sblattero D. et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014; 123 (22) 3478-3487
  CrossrefPubMedGoogle Scholar
• 40 Agostinis C, Biffi S, Garrovo C. et al. In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood 2011; 118 (15) 4231-4238
  CrossrefPubMedGoogle Scholar
• 41 Chighizola CB, Raimondo MG, Comerio C. et al. The risk of obstetric complications and the effects of treatment in women with low titer and medium-high titer anti-phospholipid antibodies. 2017 . Accessed May 8, 2020 at: https://acrabstracts.org/abstract/the-risk-of-obstetric-complications-and-the-effects-of-treatment-in-women-with-low-titer-and-medium-high-titer-anti-phospholipid-antibodies/
  Google Scholar
• 42 Lippi G, Adcock D, Favaloro EJ. Understanding the “philosophy” of laboratory hemostasis. Diagnosis (Berl) 2019; 6 (03) 223-226
  CrossrefPubMedGoogle Scholar
• 43 Bu C, Gao L, Xie W. et al. β2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum 2009; 60 (02) 559-568
  CrossrefPubMedGoogle Scholar
• 44 Kremers RMW, Zuily S, Kelchtermans H. et al. Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin. Blood Adv 2018; 2 (11) 1315-1324
  CrossrefPubMedGoogle Scholar
• 45 Ramesh S, Morrell CN, Tarango C. et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest 2011; 121 (01) 120-131
  CrossrefPubMedGoogle Scholar
• 46 Rand JH, Wu XX, Quinn AS. et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163 (03) 1193-1200
  CrossrefPubMedGoogle Scholar
• 47 Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994; 83 (09) 2532-2540
  CrossrefPubMedGoogle Scholar
• 48 de Laat B, Eckmann CM, van Schagen M, Meijer AB, Mertens K, van Mourik JA. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis 2008; 19 (08) 757-764
  CrossrefPubMedGoogle Scholar
• 49 Prinz N, Clemens N, Canisius A, Lackner KJ. Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome. Thromb Haemost 2013; 109 (03) 525-531
  Article in Thieme ConnectPubMedGoogle Scholar
• 50 Prinz N, Clemens N, Strand D. et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011; 118 (08) 2322-2332
  CrossrefPubMedGoogle Scholar
• 51 Pennings MTT, van Lummel M, Derksen RHWM. et al. Interaction of β2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost 2006; 4 (08) 1680-1690
  CrossrefPubMedGoogle Scholar
• 52 Raschi E, Chighizola CB, Grossi C. et al. β2-Glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun 2014; 55 (01) 42-50
  CrossrefPubMedGoogle Scholar
• 53 Colasanti T, Alessandri C, Capozzi A. et al. Autoantibodies specific to a peptide of β2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood 2012; 120 (16) 3360-3370
  CrossrefPubMedGoogle Scholar
• 54 Sorice M, Longo A, Capozzi A. et al. Anti-β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56 (08) 2687-2697
  CrossrefPubMedGoogle Scholar
• 55 Xia L, Zhou H, Wang T. et al. Activation of mTOR is involved in anti-β₂GPI/β₂GPI-induced expression of tissue factor and IL-8 in monocytes. Thromb Res 2017; 157: 103-110
  CrossrefPubMedGoogle Scholar
• 56 López-Pedrera C, Buendía P, Cuadrado MJ. et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54 (01) 301-311
  CrossrefPubMedGoogle Scholar
• 57 Pennings MTT, Derksen RHWM, van Lummel M. et al. Platelet adhesion to dimeric β-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost 2007; 5 (02) 369-377
  CrossrefPubMedGoogle Scholar
• 58 Zhang W, Gao F, Lu D. et al. Anti-β2 glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2′ and glycoprotein I bα. Front Med 2016; 10 (01) 76-84
  CrossrefPubMedGoogle Scholar
• 59 Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50 (09) 2911-2919
  CrossrefPubMedGoogle Scholar
• 60 Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 2012; 119 (03) 884-893
  CrossrefPubMedGoogle Scholar
• 61 Wang M, Kong X, Xie Y, He C, Wang T, Zhou H. Role of TLR-4 in anti-β2-glycoprotein I-induced activation of peritoneal macrophages and vascular endothelial cells in mice. Mol Med Rep 2019; 19 (05) 4353-4363
  PubMedGoogle Scholar
• 62 Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z. et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007; 5 (09) 1828-1834
  CrossrefPubMedGoogle Scholar
• 63 Simantov R, LaSala JM, Lo SK. et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96 (05) 2211-2219
  CrossrefPubMedGoogle Scholar
• 64 Miranda S, Billoir P, Damian L. et al. Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: role of reduced inflammation and endothelial dysfunction. PLoS One 2019; 14 (03) e0212614
  CrossrefPubMedGoogle Scholar
• 65 Canaud G, Legendre C, Terzi F. AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. Lupus 2015; 24 (03) 227-230
  CrossrefPubMedGoogle Scholar
• 66 Hsieh WT, Hsu CJ, Capraro BR. et al. Curvature sorting of peripheral proteins on solid-supported wavy membranes. Langmuir 2012; 28 (35) 12838-12843
  CrossrefPubMedGoogle Scholar
• 67 Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9 (06) 654-659
  CrossrefPubMedGoogle Scholar
• 68 Arienti G, Carlini E, Polci A, Cosmi EV, Palmerini CA. Fatty acid pattern of human prostasome lipid. Arch Biochem Biophys 1998; 358 (02) 391-395
  CrossrefPubMedGoogle Scholar
• 69 Tauro BJ, Greening DW, Mathias RA, Mathivanan S, Ji H, Simpson RJ. Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids. Mol Cell Proteomics 2013; 12 (03) 587-598
  CrossrefPubMedGoogle Scholar
• 70 Denzer K, van Eijk M, Kleijmeer MJ, Jakobson E, de Groot C, Geuze HJ. Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol 2000; 165 (03) 1259-1265
  CrossrefPubMedGoogle Scholar
• 71 Ettelaie C, Elkeeb AM, Maraveyas A, Collier MEW. p38α phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles. Biochim Biophys Acta 2013; 1833 (03) 613-621
  CrossrefPubMedGoogle Scholar
• 72 Stegmayr B, Ronquist G. Promotive effect on human sperm progressive motility by prostasomes. Urol Res 1982; 10 (05) 253-257
  CrossrefPubMedGoogle Scholar
• 73 Morelli AE, Larregina AT, Shufesky WJ. et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004; 104 (10) 3257-3266
  CrossrefPubMedGoogle Scholar
• 74 MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. Rapid secretion of interleukin-1β by microvesicle shedding. Immunity 2001; 15 (05) 825-835
  CrossrefPubMedGoogle Scholar
• 75 Calzolari A, Raggi C, Deaglio S. et al. TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 2006; 119 (Pt 21): 4486-4498
  CrossrefPubMedGoogle Scholar
• 76 Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol 1985; 101 (03) 942-948
  CrossrefPubMedGoogle Scholar
• 77 Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013; 200 (04) 373-383
  CrossrefPubMedGoogle Scholar
• 78 Parolini I, Federici C, Raggi C. et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009; 284 (49) 34211-34222
  CrossrefPubMedGoogle Scholar
• 79 Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002; 99 (11) 3962-3970
  CrossrefPubMedGoogle Scholar
• 80 Mack M, Kleinschmidt A, Brühl H. et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 2000; 6 (07) 769-775
  CrossrefPubMedGoogle Scholar
• 81 Owens III AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108 (10) 1284-1297
  CrossrefPubMedGoogle Scholar
• 82 Su Y, Deng X, Ma R, Dong Z, Wang F, Shi J. The exposure of phosphatidylserine influences procoagulant activity in retinal vein occlusion by microparticles, blood cells, and endothelium. Oxid Med Cell Longev 2018; 2018: 3658476
  PubMedGoogle Scholar
• 83 Combes V, Simon AC, Grau GE. et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104 (01) 93-102
  CrossrefPubMedGoogle Scholar
• 84 Pasquet JM, Dachary-Prigent J, Nurden AT. Calcium influx is a determining factor of calpain activation and microparticle formation in platelets. Eur J Biochem 1996; 239 (03) 647-654
  CrossrefPubMedGoogle Scholar
• 85 Hankins HM, Baldridge RD, Xu P, Graham TR. Role of flippases, scramblases and transfer proteins in phosphatidylserine subcellular distribution. Traffic 2015; 16 (01) 35-47
  CrossrefPubMedGoogle Scholar
• 86 Butenas S. Tissue factor structure and function. Scientifica (Cairo) 2012; 2012: 964862
  PubMedGoogle Scholar
• 87 Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27 (08) 1687-1693
  CrossrefPubMedGoogle Scholar
• 88 Collier MEW, Ettelaie C. Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J Biol Chem 2011; 286 (14) 11977-11984
  CrossrefPubMedGoogle Scholar
• 89 Chirinos JA, Heresi GA, Velasquez H. et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 2005; 45 (09) 1467-1471
  CrossrefPubMedGoogle Scholar
• 90 Barry OP, Kazanietz MG, Praticò D, FitzGerald GA. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. J Biol Chem 1999; 274 (11) 7545-7556
  CrossrefPubMedGoogle Scholar
• 91 Jy W, Jimenez JJ, Mauro LM. et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost 2005; 3 (06) 1301-1308
  CrossrefPubMedGoogle Scholar
• 92 Sing CE, Alexander-Katz A. Elongational flow induces the unfolding of von Willebrand factor at physiological flow rates. Biophys J 2010; 98 (09) L35-L37
  CrossrefPubMedGoogle Scholar
• 93 Wu M, Barnard J, Kundu S, McCrae KR. A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles. J Thromb Haemost 2015; 13 (10) 1928-1940
  CrossrefPubMedGoogle Scholar
• 94 Thyagarajan A, Kadam SM, Liu L. et al. Gemcitabine induces microvesicle particle release in a platelet-activating factor-receptor-dependent manner via modulation of the MAPK pathway in pancreatic cancer cells. Int J Mol Sci 2018; 20 (01) E32
  CrossrefPubMedGoogle Scholar
• 95 Velásquez M, Rojas M, Abrahams VM, Escudero C, Cadavid ÁP. Mechanisms of endothelial dysfunction in antiphospholipid syndrome: association with clinical manifestations. Front Physiol 2018; 9: 1840
  CrossrefPubMedGoogle Scholar
• 96 Chaturvedi S, McCrae KR. Clinical risk assessment in the antiphospholipid syndrome: current landscape and emerging biomarkers. Curr Rheumatol Rep 2017; 19 (07) 43
  CrossrefPubMedGoogle Scholar
• 97 Campello E, Radu CM, Tonello M. et al. Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study. Scand J Rheumatol 2018; 47 (06) 501-504
  CrossrefPubMedGoogle Scholar
• 98 Chaturvedi S, Cockrell E, Espinola R. et al. Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. Thromb Res 2015; 135 (01) 102-108
  CrossrefPubMedGoogle Scholar
• 99 Mobarrez F, Gunnarsson I, Svenungsson E. Altered β₂-glycoprotein I expression on microparticles in the presence of antiphospholipid antibodies. J Thromb Haemost 2017; 15 (09) 1799-1806
  CrossrefPubMedGoogle Scholar
• 100 Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014; 30 (01) 255-289
  CrossrefPubMedGoogle Scholar
• 101 Raiborg C, Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 2009; 458 (7237): 445-452
  CrossrefPubMedGoogle Scholar
• 102 Hicke L, Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 2003; 19 (01) 141-172
  CrossrefPubMedGoogle Scholar
• 103 Savina A, Vidal M, Colombo MI. The exosome pathway in K562 cells is regulated by Rab11. J Cell Sci 2002; 115 (Pt 12): 2505-2515
  CrossrefPubMedGoogle Scholar
• 104 Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, Basbaum C. The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene 2004; 23 (04) 956-963
  CrossrefPubMedGoogle Scholar
• 105 Bianco F, Perrotta C, Novellino L. et al. Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J 2009; 28 (08) 1043-1054
  CrossrefPubMedGoogle Scholar
• 106 Curtis AM, Wilkinson PF, Gui M, Gales TL, Hu E, Edelberg JM. p38 mitogen-activated protein kinase targets the production of proinflammatory endothelial microparticles. J Thromb Haemost 2009; 7 (04) 701-709
  CrossrefPubMedGoogle Scholar
• 107 Yang S, Zhong Q, Qiu Z. et al. Angiotensin II receptor type 1 autoantibodies promote endothelial microparticles formation through activating p38 MAPK pathway. J Hypertens 2014; 32 (04) 762-770
  CrossrefPubMedGoogle Scholar
• 108 Li M, Yu D, Williams KJ, Liu ML. Tobacco smoke induces the generation of procoagulant microvesicles from human monocytes/macrophages. Arterioscler Thromb Vasc Biol 2010; 30 (09) 1818-1824
  CrossrefPubMedGoogle Scholar
• 109 Betapudi V, Lominadze G, Hsi L, Willard B, Wu M, McCrae KR. Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway. Blood 2013; 122 (23) 3808-3817
  CrossrefPubMedGoogle Scholar
• 110 Zhu HQ, Cheng XW, Xiao LL. et al. Melatonin prevents oxidized low-density lipoprotein-induced increase of myosin light chain kinase activation and expression in HUVEC through ERK/MAPK signal transduction. J Pineal Res 2008; 45 (03) 328-334
  CrossrefPubMedGoogle Scholar